JP2009519339A - 筋細胞増殖及び分化を調節するマイクロｒｎａ - Google Patents

筋細胞増殖及び分化を調節するマイクロｒｎａ Download PDF

Info

Publication number
JP2009519339A
JP2009519339A JP2008545718A JP2008545718A JP2009519339A JP 2009519339 A JP2009519339 A JP 2009519339A JP 2008545718 A JP2008545718 A JP 2008545718A JP 2008545718 A JP2008545718 A JP 2008545718A JP 2009519339 A JP2009519339 A JP 2009519339A
Authority
JP
Japan
Prior art keywords
mir
mirna
gene
muscle
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008545718A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009519339A5 (enExample
Inventor
ワン ダジ
チェン ジャンフ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of North Carolina at Chapel Hill
Original Assignee
University of North Carolina at Chapel Hill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of North Carolina at Chapel Hill filed Critical University of North Carolina at Chapel Hill
Publication of JP2009519339A publication Critical patent/JP2009519339A/ja
Publication of JP2009519339A5 publication Critical patent/JP2009519339A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3517—Marker; Tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/10—Production naturally occurring

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2008545718A 2005-12-12 2006-12-12 筋細胞増殖及び分化を調節するマイクロｒｎａ Pending JP2009519339A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74954405P 2005-12-12 2005-12-12
PCT/US2006/047255 WO2007070483A2 (en) 2005-12-12 2006-12-12 Micrornas that regulate muscle cell proliferation and differentiation

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2013027633A Division JP5796027B2 (ja) 2005-12-12 2013-02-15 筋細胞増殖及び分化を調節するマイクロｒｎａ
JP2013253829A Division JP5740460B2 (ja) 2005-12-12 2013-12-09 筋細胞増殖及び分化を調節するマイクロｒｎａ

Publications (2)

Publication Number Publication Date
JP2009519339A true JP2009519339A (ja) 2009-05-14
JP2009519339A5 JP2009519339A5 (enExample) 2010-01-14

Family

ID=38163464

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2008545718A Pending JP2009519339A (ja) 2005-12-12 2006-12-12 筋細胞増殖及び分化を調節するマイクロｒｎａ
JP2013027633A Expired - Fee Related JP5796027B2 (ja) 2005-12-12 2013-02-15 筋細胞増殖及び分化を調節するマイクロｒｎａ
JP2013253829A Expired - Fee Related JP5740460B2 (ja) 2005-12-12 2013-12-09 筋細胞増殖及び分化を調節するマイクロｒｎａ

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2013027633A Expired - Fee Related JP5796027B2 (ja) 2005-12-12 2013-02-15 筋細胞増殖及び分化を調節するマイクロｒｎａ
JP2013253829A Expired - Fee Related JP5740460B2 (ja) 2005-12-12 2013-12-09 筋細胞増殖及び分化を調節するマイクロｒｎａ

Country Status (14)

Country Link
US (3) US8431542B2 (enExample)
EP (3) EP2671949A1 (enExample)
JP (3) JP2009519339A (enExample)
KR (2) KR101485071B1 (enExample)
CN (2) CN101448942B (enExample)
AU (1) AU2006326517B2 (enExample)
BR (1) BRPI0619755A2 (enExample)
CA (2) CA2634046A1 (enExample)
DK (1) DK1969125T3 (enExample)
ES (1) ES2387250T3 (enExample)
NZ (3) NZ569738A (enExample)
PL (1) PL1969125T3 (enExample)
PT (1) PT1969125E (enExample)
WO (1) WO2007070483A2 (enExample)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013542921A (ja) * 2010-09-13 2013-11-28 エスエヌユー アールアンドディービー ファウンデーション ｍｉＲＮＡをターゲットとした神経変性疾患の治療
JP2014503192A (ja) * 2010-11-05 2014-02-13 ミラゲン セラピューティクス 塩基修飾オリゴヌクレオチド
WO2018070510A1 (ja) * 2016-10-13 2018-04-19 国立研究開発法人国立精神・神経医療研究センター 筋分化誘導剤
JP2019512489A (ja) * 2016-03-07 2019-05-16 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ マイクロｒｎａおよびその使用方法
JP2020534349A (ja) * 2017-08-18 2020-11-26 クラミス シーオー., エルティーディー.Curamys Co., Ltd. 筋肉疾患および神経筋肉疾患の予防、治療または診断のためのｍｉＲ−１８ｂの用途
JP2021505176A (ja) * 2017-12-08 2021-02-18 ユニバーシティ オブ ワシントンＵｎｉｖｅｒｓｉｔｙ ｏｆ Ｗａｓｈｉｎｇｔｏｎ カルジオリピンのリモデリング及び心筋細胞の成熟を検出、及び促進する方法及び組成物、並びにミトコンドリア機能障害治療の関連する方法
US11597930B2 (en) 2020-04-02 2023-03-07 Mirecule, Inc. Targeted inhibition using engineered oligonucleotides
JP2023515672A (ja) * 2020-03-02 2023-04-13 テナヤ セラピューティクス， インコーポレイテッド 心筋細胞発現マイクロｒｎａによる遺伝子ベクター制御

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006107826A2 (en) 2005-04-04 2006-10-12 The Board Of Regents Of The University Of Texas System Micro-rna's that regulate muscle cells
CN101448942B (zh) 2005-12-12 2014-04-23 北卡罗来纳大学查珀尔希尔分校 调节肌细胞增殖和分化的microrna
EP2434017A3 (en) 2006-08-01 2012-09-05 Board of Regents of the University of Texas System Identification of a micro-RNA that activates expression of beta-myosin heavy chain
GB2440782A (en) * 2006-08-04 2008-02-13 Cesare Peschle Uses and compositions comprising miRNAs
HUE037173T2 (hu) 2006-08-08 2018-08-28 Univ Bonn Rheinische Friedrich Wilhelms 5'-Foszfát-oligonukleotidok szerkezete és alkalmazása
CA2728575A1 (en) 2007-06-29 2009-01-08 Boston Biomedical, Inc. Enabling the use of long dsrna for gene targeting in mammalian and other selected animal cells
WO2009018492A2 (en) * 2007-07-31 2009-02-05 The Board Of Regents Of The University Of Texas System Micro-rnas that control myosin expression and myofiber identity
ES2621161T3 (es) * 2007-07-31 2017-07-03 The Board Of Regents Of The University Of Texas System Familia de micro-ARN que modula la fibrosis y usos de la misma
CA2716343A1 (en) * 2008-02-21 2009-08-27 The Board Of Regents Of The University Of Texas System Micro-rnas that modulate smooth muscle proliferation and differentiation and uses thereof
CA2718520C (en) * 2008-03-17 2020-01-07 The Board Of Regents Of The University Of Texas System Identification of micro-rnas involved in neuromuscular synapse maintenance and regeneration
EP2297323A1 (en) 2008-05-21 2011-03-23 Hartmann, Gunther 5' triphosphate oligonucleotide with blunt end and uses thereof
AU2009257663B2 (en) * 2008-06-09 2014-06-26 New York Medical College Compositions comprising cardiac stem cells overexpressing specific microRNA and methods of their use in repairing damaged myocardium
GB0811715D0 (en) * 2008-06-26 2008-07-30 Angeletti P Ist Richerche Bio Therapeutic agents
MX2011008190A (es) 2009-02-04 2011-10-06 Univ Texas Direccionamiento dual de mir-208 y mir-499 en el tratamiento de trastornos cardiacos.
DK2427472T3 (en) 2009-05-05 2016-09-12 Miragen Therapeutics Lipophilic polynukleotidkonjugater
EP2435570A1 (en) * 2009-05-25 2012-04-04 Carola Ponzetto Differentiation therapy for sarcomas
US20130034850A1 (en) * 2010-02-26 2013-02-07 Natinal Center of Neurology and Psychiatry Marker for detecting myogenic disease and detection method using the same
KR20130069587A (ko) * 2010-04-08 2013-06-26 교토후고리츠다이가쿠호진 체액 유래 검체를 사용한 횡문근육종의 검출 방법
US9987309B2 (en) * 2010-07-08 2018-06-05 Duke University Direct reprogramming of cells to cardiac myocyte fate
EP2638158A4 (en) * 2010-11-11 2015-07-15 Univ Miami COMPOSITIONS, CELLS, KITS AND METHODS FOR AUTOLOGOUS STEM CELL THERAPY
US8642751B2 (en) 2010-12-15 2014-02-04 Miragen Therapeutics MicroRNA inhibitors comprising locked nucleotides
EP2508530A1 (en) 2011-03-28 2012-10-10 Rheinische Friedrich-Wilhelms-Universität Bonn Purification of triphosphorylated oligonucleotides using capture tags
CN103814131A (zh) * 2011-05-09 2014-05-21 格拉斯哥大学理事会 在肺动脉高血压的治疗中调控microrna的方法
US20140221464A1 (en) * 2011-07-01 2014-08-07 Board Of Regents, The University Of Texas System Compositions and Methods for Treating Skeletal Myopathy
EP2731422B1 (en) * 2011-07-12 2017-08-09 Mart Saarma miRNA antagonists for use in treating neurodegenerative disorders by increasing expression of GDNF
US9018188B2 (en) 2011-09-13 2015-04-28 Ottawa Hospital Research Institute MicroRNA inhibitors
US9428749B2 (en) * 2011-10-06 2016-08-30 The Board Of Regents, The University Of Texas System Control of whole body energy homeostasis by microRNA regulation
JP6208228B2 (ja) 2012-06-21 2017-10-04 ミラゲン セラピューティクス， インコーポレイテッド ロックド核酸モチーフを含むオリゴヌクレオチドベースの阻害剤
EP2712870A1 (en) 2012-09-27 2014-04-02 Rheinische Friedrich-Wilhelms-Universität Bonn Novel RIG-I ligands and methods for producing them
US9752143B2 (en) 2013-03-15 2017-09-05 MiRagen Therapeutics, Inc. Locked nucleic acid inhibitor of miR-145 and uses thereof
EP2970968B1 (en) 2013-03-15 2018-01-10 Miragen Therapeutics, Inc. Bridged bicyclic nucleosides
WO2014201254A1 (en) * 2013-06-12 2014-12-18 University Of Washington Through Its Center For Commercialization Methods for maturing cardiomyocytes and uses thereof
CN103710387B (zh) * 2013-12-25 2015-10-14 天津农学院 一种促进牛骨骼肌卫星细胞体外增殖的方法
JP6566536B2 (ja) * 2014-06-16 2019-08-28 国立大学法人山口大学 フォワードプライマー
CN104498497A (zh) * 2014-12-10 2015-04-08 山东农业大学 一种与奶山羊乳腺上皮细胞凋亡相关的miRNA及其在奶山羊育种中的应用
US10620109B2 (en) 2015-01-14 2020-04-14 Kyoto University Method for selecting skeletal muscle progenitor cell
EP3247716A4 (en) 2015-01-20 2018-10-17 Miragen Therapeutics, Inc. Mir-92 inhibitors and uses thereof
CN104877960B (zh) * 2015-06-01 2017-09-19 东北农业大学 miR‑2400显著促进牛骨骼肌卫星细胞增殖的生物功能
CN105713972A (zh) * 2016-03-16 2016-06-29 上海中医药大学 miRNA在制备药物性心脏病生物标志物中的用途
CN106399473B (zh) * 2016-08-23 2019-12-06 南京大学 检测和评价力量训练效果的miRNA标志物或其组合及其应用
WO2018080658A1 (en) * 2016-10-27 2018-05-03 Aalborg University Therapeutic targeting of a microrna to treat duchenne muscular dystrophy
CN108324946B (zh) * 2017-01-20 2022-02-18 上海市东方医院 miRNA708、和/或301簇的微小RNA在改善心脏功能方面的应用
CN107096030A (zh) * 2017-03-20 2017-08-29 天津农学院 一种利用miR‑143抑制剂延缓小鼠失神经后肌肉萎缩的方法
WO2018187523A2 (en) * 2017-04-05 2018-10-11 University Of Cincinnati Promotion of cardiomyocyte proliferation and regenerative treatment of the heart by inhibition of microrna-128
WO2019035690A1 (ko) * 2017-08-18 2019-02-21 서울대학교병원 근육 질환 및 신경근육 질환 예방, 치료 또는 진단을 위한 miR-18b의 용도
JP7318166B2 (ja) * 2018-03-14 2023-08-01 ベス イスラエル デアコネス メディカル センター マイクロｒｎａ２２の阻害剤
CN108690846A (zh) * 2018-04-17 2018-10-23 上海大学 抑制MiR-29b基因表达的应用
CN108823209B (zh) * 2018-07-18 2021-04-09 华中农业大学 骨骼肌特异性启动子及应用
AU2019333315B2 (en) 2018-08-30 2022-09-29 Tenaya Therapeutics, Inc. Cardiac cell reprogramming with myocardin and ASCL1
CN111041052B (zh) * 2019-12-30 2021-05-28 嘉兴学院 mir-206在抑制猪脂肪细胞内的甘油三酯生成以及瘦肉猪育种中的应用
CN112266912A (zh) * 2020-10-22 2021-01-26 上海大学 靶向miR-29b的gRNA、AAV8-CRISPR/Cas9系统及其应用
WO2023034966A1 (en) * 2021-09-03 2023-03-09 The University Of North Carolina At Chapel Hill Compositions and methods of using the same for treating disorders associated with thymosin βeta 4
CN114480672B (zh) * 2022-02-22 2023-08-15 青岛农业大学 一种通过miR-145筛选高产肉率碱地黑牛的方法
CN114748497B (zh) * 2022-04-27 2024-10-18 广州市妇女儿童医疗中心 一种调控子宫肌收缩的miRNA分子miR-206及其应用
CN115181722B (zh) * 2022-08-30 2024-06-11 江苏农牧科技职业学院 一种鹅骨骼肌卫星细胞的体外分离和培养方法
CN117511884B (zh) * 2023-12-06 2024-06-11 中国农业科学院兰州畜牧与兽药研究所 Rtl1在抑制牦牛成肌细胞分化中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004076622A2 (en) * 2003-02-10 2004-09-10 National Institute Of Advanced Industrial Science And Technology Regulation of gene expression by dna interference

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7803782B2 (en) * 2003-05-28 2010-09-28 Roche Madison Inc. Intravenous delivery of polynucleotides to cells in mammalian limb
US20050124566A1 (en) 2001-05-18 2005-06-09 Sirna Therapeutics, Inc. RNA interference mediated inhibition of myostatin gene expression using short interfering nucleic acid (siNA)
EP2390328A1 (en) * 2001-09-28 2011-11-30 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. MicroRNA molecules
US7781415B2 (en) * 2003-02-07 2010-08-24 Roche Madison Inc. Process for delivering sirna to cardiac muscle tissue
SE521643C2 (sv) * 2003-02-26 2003-11-18 Scania Cv Publ Kraftöverföring med från en huvudväxel skild rangeväxel
EP2314688B1 (en) * 2004-11-12 2014-07-16 Asuragen, Inc. Methods and compositions involving miRNA and miRNA inhibitor molecules
WO2006107826A2 (en) 2005-04-04 2006-10-12 The Board Of Regents Of The University Of Texas System Micro-rna's that regulate muscle cells
WO2006113540A2 (en) 2005-04-14 2006-10-26 Duke University Use of ntrosylated hemoglobin
CN101448942B (zh) 2005-12-12 2014-04-23 北卡罗来纳大学查珀尔希尔分校 调节肌细胞增殖和分化的microrna

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004076622A2 (en) * 2003-02-10 2004-09-10 National Institute Of Advanced Industrial Science And Technology Regulation of gene expression by dna interference

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN6012041773; ＺＨＡＯ，Ｙ．　ｅｔ　ａｌ: 'Ｓｅｒｕｍ　ｒｅｓｐｏｎｓｅ　ｆａｃｔｏｒ　ｒｅｇｕｌａｔｅｓ　ａ　ｍｕｓｃｌｅ-ｓｐｅｃｉｆｉｃ　ｍｉｃｒｏＲＮＡ　ｔｈａｔ　ｔａｒｇｅｔｓ　Ｈａｎｄ２　ｄｕｒｉｎｇ　ｃａｒｄｉｏｇｅｎｅｓｉｓ' Ｎａｔｕｒｅ Ｖｏｌ．４３６，　Ｎｏ．７０４８, 2005, ｐ．２１４-２０ *
JPN6012041774; ＺＨＡＯ，Ｘ．　ｅｔ　ａｌ: 'Ｒｅｇｕｌａｔｉｏｎ　ｏｆ　ＭＥＦ２　ｂｙ　ｈｉｓｔｏｎｅ　ｄｅａｃｅｔｙｌａｓｅ　４-　ａｎｄ　ＳＩＲＴ１　ｄｅａｃｅｔｙｌａｓｅ-ｍｅｄｉａｔｅｄ　ｌｙｓｉｎｅ　ｍｏｄｉｆｉｃａｔｉｏｎｓ' Ｍｏｌ　Ｃｅｌｌ　Ｂｉｏｌ Ｖｏｌ．２５，　Ｎｏ．１９, 2005, ｐ．８４５６-６４ *
JPN6012041775; ＳＯＫＯＬ，Ｎ．Ｓ．　ｅｔ　ａｌ: 'Ｍｅｓｏｄｅｒｍａｌｌｙ　ｅｘｐｒｅｓｓｅｄ　Ｄｒｏｓｏｐｈｉｌａ　ｍｉｃｒｏＲＮＡ-１　ｉｓ　ｒｅｇｕｌａｔｅｄ　ｂｙ　Ｔｗｉｓｔ　ａｎｄ　ｉｓ　ｒｅｑｕｉｒｅｄ　ｉｎ　ｍｕｓｃｌｅｓ　ｄｕｒｉｎｇ' Ｇｅｎｅｓ　Ｄｅｖ Ｖｏｌ．１９，　Ｎｏ．１９, 2005, ｐ．２３４３-５４ *

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013542921A (ja) * 2010-09-13 2013-11-28 エスエヌユー アールアンドディービー ファウンデーション ｍｉＲＮＡをターゲットとした神経変性疾患の治療
JP2014503192A (ja) * 2010-11-05 2014-02-13 ミラゲン セラピューティクス 塩基修飾オリゴヌクレオチド
US11655469B2 (en) 2016-03-07 2023-05-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services MicroRNAs and methods of their use
JP2019512489A (ja) * 2016-03-07 2019-05-16 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ マイクロｒｎａおよびその使用方法
JPWO2018070510A1 (ja) * 2016-10-13 2019-08-08 国立研究開発法人国立精神・神経医療研究センター 筋分化誘導剤
US10934543B2 (en) 2016-10-13 2021-03-02 National Center Of Neurology And Psychiatry Inducer of muscle differentiation
JP7005020B2 (ja) 2016-10-13 2022-02-10 国立研究開発法人国立精神・神経医療研究センター 筋分化誘導剤
WO2018070510A1 (ja) * 2016-10-13 2018-04-19 国立研究開発法人国立精神・神経医療研究センター 筋分化誘導剤
JP2020534349A (ja) * 2017-08-18 2020-11-26 クラミス シーオー., エルティーディー.Curamys Co., Ltd. 筋肉疾患および神経筋肉疾患の予防、治療または診断のためのｍｉＲ−１８ｂの用途
US11286484B2 (en) 2017-08-18 2022-03-29 Curamys Co., Ltd. Use of miR-18b for prevention, treatment, or diagnosis of muscle disease and neuromuscular disease
US11891604B2 (en) 2017-08-18 2024-02-06 Curamys Co., Ltd. Use of miR-18b for prevention, treatment, or diagnosis of muscle disease and neuromuscular disease
JP2021505176A (ja) * 2017-12-08 2021-02-18 ユニバーシティ オブ ワシントンＵｎｉｖｅｒｓｉｔｙ ｏｆ Ｗａｓｈｉｎｇｔｏｎ カルジオリピンのリモデリング及び心筋細胞の成熟を検出、及び促進する方法及び組成物、並びにミトコンドリア機能障害治療の関連する方法
JP7279953B2 (ja) 2017-12-08 2023-05-23 ユニバーシティ オブ ワシントン カルジオリピンのリモデリング及び心筋細胞の成熟を検出、及び促進する方法及び組成物、並びにミトコンドリア機能障害治療の関連する方法
JP2023515672A (ja) * 2020-03-02 2023-04-13 テナヤ セラピューティクス， インコーポレイテッド 心筋細胞発現マイクロｒｎａによる遺伝子ベクター制御
US11597930B2 (en) 2020-04-02 2023-03-07 Mirecule, Inc. Targeted inhibition using engineered oligonucleotides
US11795459B2 (en) 2020-04-02 2023-10-24 Mirecule, Inc. Targeted inhibition using engineered oligonucleotides
US12104157B2 (en) 2020-04-02 2024-10-01 Mirecule, Inc. Targeted inhibition using engineered oligonucleotides

Also Published As

Publication number Publication date
ES2387250T3 (es) 2012-09-19
DK1969125T3 (da) 2012-07-23
CN101448942A (zh) 2009-06-03
EP1969125A4 (en) 2010-10-20
US20130225658A1 (en) 2013-08-29
AU2006326517A1 (en) 2007-06-21
CN101448942B (zh) 2014-04-23
JP2014094943A (ja) 2014-05-22
US9072764B2 (en) 2015-07-07
WO2007070483A9 (en) 2011-06-16
NZ602571A (en) 2014-03-28
EP2497827A1 (en) 2012-09-12
NZ569738A (en) 2012-03-30
BRPI0619755A2 (pt) 2011-10-18
KR101485071B1 (ko) 2015-01-26
CA2903764A1 (en) 2007-06-21
CA2634046A1 (en) 2007-06-21
US8431542B2 (en) 2013-04-30
NZ593688A (en) 2013-01-25
KR20140130562A (ko) 2014-11-10
PL1969125T3 (pl) 2012-11-30
JP5796027B2 (ja) 2015-10-21
US20130225665A1 (en) 2013-08-29
US20100292297A1 (en) 2010-11-18
AU2006326517B2 (en) 2013-02-21
JP5740460B2 (ja) 2015-06-24
KR20080080177A (ko) 2008-09-02
CN104027818A (zh) 2014-09-10
EP1969125A2 (en) 2008-09-17
EP1969125B1 (en) 2012-06-13
EP2671949A1 (en) 2013-12-11
JP2013126996A (ja) 2013-06-27
WO2007070483A2 (en) 2007-06-21
WO2007070483A3 (en) 2008-07-24
PT1969125E (pt) 2012-08-16

Similar Documents

Publication Publication Date Title
JP5740460B2 (ja) 筋細胞増殖及び分化を調節するマイクロｒｎａ
US10612026B2 (en) Pharmaceutical composition for treating cancer comprising microrna as active ingredient
Yan et al. Dynamic expression of microRNA-127 during porcine prenatal and postnatal skeletal muscle development
AU2013202293B2 (en) MicroRNAs that regulate muscle cell proliferation and differentiation
US20100305195A1 (en) microrna mediator of cardiomyopathy and heart failure
HK1192280A (en) Micro-rna mir-145 that regulate muscle cell proliferation and differentiation
MX2008007552A (es) Microacidos ribonucleicos que regulan la proliferacion y diferenciacion de celulas musculares
Guess Characterization of microRNA Function During Skeletal Myogenesis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091117

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20091117

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120816

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121112

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121119

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121210

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121217

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130111

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130215

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20130218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130319

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130909

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130917

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131209

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140106